What is RCEL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.41B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RCEL?

P/E (TTM) is n/a and 52-week range is $3.22 to $13.49 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RCEL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RCEL?

The company profile lists revenue (TTM) near $76M, net income (TTM) near $-4.31B, EPS (TTM) near $-1.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is AVITA Medical Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Valencia California, California, US, 30.8M shares outstanding, ISIN US05380C1027 when available from company profile and filing metadata.

AVITA Medical Inc

$RCEL

Health Care · Biotechnology

IR Run Scenarios

$13.21

-0.90%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 226 full-time employees. The company went IPO on 2012-03-18. The firm solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.

Employees

226

Website

www.avitamedical.com/

IPO

2012-03-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)